Citations

Showing 10 of 108152 citations.

Grand rounds education in neurology, with a focus on headache medicine
Burish, Mark J. , Ahmed, Zubair , Rosen, Noah , Ahmed, Zubair A , Singh, Rashmi B. Halker

Mayo Clinic

Headache: The Journal of Head and Face Pain | May 15, 2021 | Volume: 61 | Issue: 7 | Pages: 1077-1085

10.1111/head.14116 | PMID 33990947 Get It

Abstract Objective To quantify the proportion of headache‐related grand rounds in academic neurology programs and to compare this with adult neurology residency director views on the need for an increase in headache‐related grand rounds. Background Although headache are among the most prevalent and most burdensome neurologic conditions, headache medicine is often considered underrepresented in neurology departments. Additionally, prior studies have shown that many neurology residency directors feel that training programs do not include an adequate amount of exposure to headache clinics or headache‐related didactics. One important aspect of didactic education in neurology departments is adult neurology grand rounds. Previous publications have evaluated neither the proportion of headache‐related grand rounds in academic neurology departments nor the residency program directors’ views on appropriate amount of headache‐related grand rounds. Our study has attempted to quantify this information to elucidate opportunities to improve practice educational gaps. Methods In this cross‐sectional study, we surveyed adult neurology residency directors (from the Accreditation Council for Graduate Medical Education [ACGME] listing of academic adult neurology residency programs) between October 2018 and September 2019. In addition, we used two methods to obtain the proportion of headache‐related grand rounds in neurology: (1) emailing residency directors a questionnaire asking for a list of prior grand rounds topics and (2) an online search for each academic neurology program. Results First, for our grand rounds analysis, headache medicine consisted of 3.7% of the lectures in 2017–2018 and 6.3% of the lectures in 2018–2019 (average of each institution; 17 institutions and 411 total lectures in 2017–2018, 21 institutions and 463 total lectures in 2018–2019). The most common number of lectures on headache medicine for each grand rounds series was zero (for 7 of 17 grand rounds series in 2017–2018 and 7 of 21 in 2018–2019), followed closely by one lecture (for 6 of 17 grand rounds series in 2017–2018 and 6 of 21 in 2018–2019). Second, for our survey, the response rate was 19.3% (29/150). No residency director thought their institution had too many grand rounds dedicated to headache medicine, and 62.1% (18/29) thought they had an adequate amount of headache grand rounds. Within the survey responders, 75.9% (22/29) of adult neurology residency programs have a board‐certified headache specialist at their institution. Conclusions Although most adult neurology residency directors believe that headache is adequately represented in adult neurology grand rounds, headache medicine makes up 4%–6% of all neurology grand rounds. Compared with other neurology subspecialties and the other core ACGME milestones, headache makes up the fewest grand rounds lectures that were assessed in this study.
Restorative Therapies for Erectile Dysfunction: Position Statement From the Sexual Medicine Society of North America (SMSNA)
Liu, James L. , Chu, Kevin Y. , Gabrielson, Andrew , Wang, Run , Trost, Landon , Brock, Gerald, Mulhall, John P. , Bivalacqua, Trinity J. , Broderick, Gregory, Broderick, Gregory A. , Davies, Kelvin Paul , Ramasamy, Ranjith

Mayo Clinic

Sexual Medicine | May 14, 2021 | Volume: 9 | Issue: 3 | Pages: 100343-100343

10.1016/j.esxm.2021.100343 | PMID 34000480 Get It

Abstract Introduction Current non-invasive treatments for erectile dysfunction (ED) include oral medications, intracavernosal injections, and vacuum-assisted devices. Though these therapies work well for many, a subset of patients have contraindications or are unsatisfied with these options. Restorative therapies for ED are a new frontier of treatments focused on regenerating diseased tissue and providing a potential “cure” for ED. Aim The aim of this position statement is to examine existing clinical trial data for restorative therapies and identify elements that require further research before widespread adoption. Methods A literature review was performed to identify all clinical trials performed with regenerative therapy for ED. This includes treatments such as stem cell therapy (SCT), platelet rich plasma (PRP), and restorative related technologies like low-intensity shockwave therapy (LiSWT). Main Outcome Measures Most clinical trials in restorative therapies were assessed for safety, feasibility, or efficacy. This included recording adverse events, changes in sexual function and erectile function questionnaires, and diagnostics measures. Results To date there is an absence of robust clinical data supporting the efficacy of restorative therapies regarding ED, though technologies such as LiSWT have established relative safety. Conclusions Restorative therapies are a promising technology that represents a new frontier of treatment geared towards reversing disease pathology rather than just treating symptoms. However, current published clinical studies are limited. Future work needs to be adequately powered, multi-center, randomized, sham/placebo-controlled trials in well-characterized patient populations to ensure safety and demonstrate efficacy. Until these studies are done, restorative therapies should be reserved for clinical trials and not offered in routine clinical practice.
Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine
Tassorelli, Cristina , Diener, Hans‐Christoph , Silberstein, Stephen D. , Goadsby, Peter J. , Yuan, Hsiangkuo , Martinelli, Daniele , Hoek, Thomas C. van den , Deen, Marie , Ashina, Messoud , Goadsby, Peter J , Magis, Delphine , Martinelli, Daniele , Deen, Marie , Silberstein, Stephan D , Diener, Hans-Christoph , Ashina, Messoud , Yuan, Hsiangkuo , Dodick, David W. , Jensen, Rigmor , Pozo‐Rosich, Patricia , Terwindt, Gisela M.

Mayo Clinic

Cephalalgia | May 14, 2021 | Volume: 41 | Issue: 11-12 | Pages: 1135-1151

10.1177/03331024211010413 | PMID 33990161 Get It

Background Although the European Medicines Agency and the US Food and Drug Administration have cleared several devices that use neuromodulation to provide clinical benefits in the acute or preventive treatment of migraine, the Clinical Trials Committee of the International Headache Society has not developed guidelines specifically for clinical trials of neuromodulation devices. In recognition of the distinct needs and challenges associated with their assessment in controlled trials, the Committee provides these recommendations for optimizing the design and conduct of controlled trials of neuromodulation devices for the acute and/or preventive treatment of migraine. Methods An international group of headache scientists and clinicians with expertise in neuromodulation evaluated clinical trials involving neuromodulation devices that have been published since 2000. The Clinical Trials Committee incorporated findings from this expert analysis into a new guideline for clinical trials of neuromodulation devices for the treatment of migraine. Results Key terms were defined and recommendations provided relative to the assessment of neuromodulation devices for acute treatment in adults, preventive treatment in adults, and acute and preventive treatment in children and adolescents. Ethical and administrative responsibilities were outlined, and a bibliography of previous research involving neuromodulation devices was created. Conclusions Adoption of these recommendations will improve the quality of evidence regarding this important area in migraine treatment.
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)
Ballman, Karla A., Halabi, Susan , Atherton, Pamela J., Mortazavi, Amir , Sweeney, Christopher J. , Stadler, Walter M. , Teply, Benjamin A. , Picus, Joel , Tagawa, Scott T. , Katragadda, Sreedhar , Vaena, Daniel A. , Misleh, Jamal , Flaig, Thomas W. , Bajorin, Dean F. , Hahn, Olwen, Rosenberg, Jonathan E , Halabi, Susan , Mortazavi, Amir , Sweeney, Christopher , Stadler, Walter M , Teply, Benjamin A , Picus, Joel , Tagawa, Scott T , Hoimes, Christopher , Flaig, Thomas W , Bajorin, Dean , Morris, Michael J , Ballman, Karla A., Atherton, Pamela J., Plimack, Elizabeth R. , Dreicer, Robert , Small, Eric J. , Morris, Michael J.

Mayo Clinic

Journal of Clinical Oncology | May 14, 2021 | Volume: 39 | Issue: 22 | Pages: 2486-2496

10.1200/jco.21.00286 | PMID 33989025 Get It

PURPOSE The combination of gemcitabine and cisplatin (GC) is a standard therapy for metastatic urothelial carcinoma. Based on data that angiogenesis plays a role in urothelial carcinoma growth and progression, a randomized placebo-controlled trial was performed with the primary objective of testing whether patients treated with GC and bevacizumab (GCB) have superior overall survival (OS) than patients treated with GC and placebo (GCP). PATIENTS AND METHODS Between July 2009 and December 2014, 506 patients with metastatic urothelial carcinoma without prior chemotherapy for metastatic disease and no neoadjuvant or adjuvant chemotherapy within 12 months were randomly assigned to receive either GCB or GCP. The primary end point was OS, with secondary end points of progression-free survival, objective response, and toxicity. RESULTS With a median follow-up of 76.3 months among alive patients, the median OS was 14.5 months for patients treated with GCB and 14.3 months for patients treated with GCP (hazard ratio for death = 0.87; 95% CI, 0.72 to 1.05; two-sided stratified log-rank P = .14). The median progression-free survival was 8.0 months for GCB and 6.7 months for GCP (hazard ratio = 0.77; 95% CI, 0.63 to 0.95; P = .016). The proportion of patients with grade 3 or greater adverse events did not differ significantly between both arms, although increased bevacizumab-related toxicities such as hypertension and proteinuria occurred in the bevacizumab-treated arm. CONCLUSION The addition of bevacizumab to GC did not result in improved OS. The observed median OS of about 14 months is consistent with prior phase III trials of cisplatin-based chemotherapy.
Multimodal guided wave inversion for arterial stiffness: methodology and validation in phantoms
Roy, Tuhin , Urban, Matthew W. , Xu, Yingzheng , Greenleaf, James F. , Guddati, Murthy N. , Urban, Matthew W , Greenleaf, James

Mayo Clinic

Physics in Medicine & Biology | May 14, 2021 | Volume: 66 | Issue: 11 | Pages: 115020

10.1088/1361-6560/ac01b7 | PMID 34061042 Get It

Abstract Arterial stiffness is an important biomarker for many cardiovascular diseases. Shear wave elastography is a recent technique aimed at estimating local arterial stiffness using guided wave inversion (GWI), i.e. matching the computed and measured wave dispersion. This paper develops and validates a new GWI approach by synthesizing various recent observations and algorithms: (a) refinements to signal processing to obtain more accurate experimental dispersion curves; (b) an efficient forward model to compute theoretical dispersion curves for immersed, incompressible cylindrical waveguides; (c) an optimization framework based on the recent observation that the measured dispersion curve is multimodal, i.e. it matches for not one but two different wave modes in two different frequency ranges. The resulting inversion approach is validated using extensive experimental data from rubber tube phantoms, not only for modulus estimation but also to simultaneously estimate modulus and wall thickness. The observations indicate that the modulus estimates are best performed with the information on wall thickness. The approach, which takes less than half a minute to run, is shown to be accurate, with the modulus estimated with less than 4% error for 70% of the experiments.
A novel method for Causal Structure Discovery from EHR data: A demonstration on type-2 diabetes mellitus
Shen, Xinpeng , Ma, Sisi , Vemuri, Prashanthi , Castro, M. Regina , Simon, György , Vemuri, Prashanthi , Ma, Sisi , Caraballo, Pedro J.

Mayo Clinic

No container title available | May 14, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-486814/v1 Get It

Abstract Modern AI-based clinical decision support models owe their success in part to the very large number of predictors they use. Safe and robust decision support, especially for intervention planning, requires causal, not associative, relationships. Traditional methods of causal discovery, clinical trials and extracting biochemical pathways, are resource intensive and may not scale up to the number and complexity of relationships sufficient for precision treatment planning. Computational causal structure discovery (CSD) from electronic health records (EHR) data can represent a solution, however, current CSD methods fall short on EHR data. This paper presents a CSD method tailored to the EHR data. The application of the proposed methodology was demonstrated on type-2 diabetes mellitus. A large EHR dataset from Mayo Clinic was used as development cohort, and another large dataset from an independent health system, M Health Fairview, as external validation cohort. The proposed method achieved very high recall (.95) and substantially higher precision than the general-purpose methods (.84 versus .29, and .55). The causal relationships extracted from the development and external validation cohorts had a high (81%) overlap. Due to the adaptations to EHR data, the proposed method is more suitable for use in clinical decision support than the general-purpose methods.
Human Gut Microbiota–associated Gastrointestinal Malignancies: A Comprehensive Review
Bonde, Apurva , Daly, Sean , Kirsten, Julia , Kondapaneni, Sainath , Mellnick, Vincent M. , Menias, Christine O. , Katabathina, Venkata S. , Mellnick, Vincent , Daly, Sean

Mayo Clinic

RadioGraphics | May 14, 2021 | Volume: 41 | Issue: 4 | Pages: E1103-E1122

10.1148/rg.2021200168 | PMID 33989072 Get It

Outcomes of Enhanced Recovery After Surgery Protocols Versus Conventional Management in Patients Undergoing Bariatric Surgery
Vico, Tamara Díaz , Cheng, Yilon Lima , Bowers, Steven P. , Arasi, Lisa C., Elli, Enrique F. , Díaz-Vico, Tamara, Chadha, Ryan

Mayo Clinic

Journal of Laparoendoscopic & Advanced Surgical Techniques | May 14, 2021 | Volume: 32 | Issue: 2 | Pages: 176-182

10.1089/lap.2020.0783 | PMID 33989060 Get It

Global Perspective on Kidney Transplantation: Thailand
Larpparisuth, Nuttasith , Cheungpasitporn, Wisit , Lumpaopong, Adisorn, Cheungpasitporn, Wisit

Mayo Clinic

Kidney360 | May 14, 2021 | Volume: 2 | Issue: 7 | Pages: 1163-1165

10.34067/kid.0002102021 | PMID 35368352 Get It

Ramadan fasting: recommendations for patients with cardiovascular disease
Akhtar, Abid Mohammed , Ghouri, Nazim , Chahal, C. Anwar A. , Patel, Riyaz , Sattar, Naveed , Waqar, Salman , Khanji, Mohammed Y , Sattar, Naveed , Khanji, Mohammed Yunus , Chahal, Choudhary Anwar A , Ricci, Fabrizio

Mayo Clinic

Heart | May 14, 2021 | Volume: 108 | Issue: 4 | Pages: 258-265

10.1136/heartjnl-2021-319273 | PMID 33990414 Get It

Ramadan fasting is observed by most of the 1.8 billion Muslims around the world. It lasts for 1 month per the lunar calendar year and is the abstention from any food and drink from dawn to sunset. While recommendations on ‘safe’ fasting exist for patients with some chronic conditions, such as diabetes mellitus, guidance for patients with cardiovascular disease is lacking. We reviewed the literature to help healthcare professionals educate, discuss and manage patients with cardiovascular conditions, who are considering fasting. Studies on the safety of Ramadan fasting in patients with cardiac disease are sparse, observational, of small sample size and have short follow-up. Using expert consensus and a recognised framework, we risk stratified patients into ‘low or moderate risk’, for example, stable angina or non-severe heart failure; ‘high risk’, for example, poorly controlled arrhythmias or recent myocardial infarction; and ‘very high risk’, for example, advanced heart failure. The ‘low-moderate risk’ group may fast, provided their medications and clinical conditions allow. The ‘high’ or ‘very high risk’ groups should not fast and may consider safe alternatives such as non-consecutive fasts or fasting shorter days, for example, during winter. All patients who are fasting should be educated before Ramadan on their risk and management (including the risk of dehydration, fluid overload and terminating the fast if they become unwell) and reviewed after Ramadan to reassess their risk status and condition. Further studies to clarify the benefits and risks of fasting on the cardiovascular system in patients with different cardiovascular conditions should help refine these recommendations.